Physician profile
Marcus James Hershey
NPI 1730568502
$910.19
in general payments reported to CMS, 2019-2025
14 companies · $319 in 2025
The $319 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $125 · 2021: $59.37 · 2022: $43.68 · 2023: $252 · 2024: $111 · 2025: $319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $683.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $682.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $299.41 | 2023-2025 | Nucala |
| Genzyme Corporation | $251.32 | 2021-2023 | |
| Medtronic USA, INC. | $78.53 | 2020 | |
| Alk-Abello, INC | $38.18 | 2020-2023 | Odactra, Grastek |
| Intersect Ent, INC. | $35.00 | 2020 | |
| Medtronic, INC. | $31.80 | 2024 | Propel |
| Inspire Medical Systems, INC. | $31.13 | 2025 | Inspire |
| Integra Lifesciences Corporation | $27.55 | 2024 | Relieva Spinplus Nav, Inspira Air, Acclarent Aera |
| Regeneron Healthcare Solutions, INC. | $26.19 | 2024 | Dupixent |
| Cochlear Americas | $25.61 | 2024 | Baha, Osia Osi300 Implant, Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode |
| Astrazeneca Pharmaceuticals LP | $21.79 | 2025 | Tezspire |
| United Therapeutics Corporation | $14.60 | 2022 | |
| Greer Laboratories, INC. | $14.54 | 2022 | |
| Novo Nordisk INC | $14.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcus Hershey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.